Medical Solutions Supplier

medsolsupplier.com

Since 1994, Medical Solutions Supplier has distributed breakthrough products that dramatically improve the quality of life for patients suffering from a variety of chronic conditions. Compression Pump Therapy consultants located throughout the country provide personal service to health care professionals and patients - making it easy to provide long term solutions and hope for healing for conditions such as lymphedema, venous disease, chronic wounds and arterial disease.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

news image

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More

AIKIDO PHARMA ADDS ARTIFICIAL INTELLIGENCE LEADER TO ADVISORY BOARD

PR Newswire | March 20, 2020

news image

AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company's Advisory Board.Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Currently he is founder and Executive Chairman of technology companies in the general AI and specialized AI-driven FinTech and MarTech space, CLOUD computing and IT Infrastructure Management, and enterprise software, including:...

Read More

Business Insights, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

news image

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More

Pharma Tech

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

news image

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More
news image

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More
news image

AIKIDO PHARMA ADDS ARTIFICIAL INTELLIGENCE LEADER TO ADVISORY BOARD

PR Newswire | March 20, 2020

AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company's Advisory Board.Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Currently he is founder and Executive Chairman of technology companies in the general AI and specialized AI-driven FinTech and MarTech space, CLOUD computing and IT Infrastructure Management, and enterprise software, including:...

Read More
news image

Business Insights, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More
news image

Pharma Tech

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More